Tvardi Therapeutics (NASDAQ:TVRD) Trading 2.6% Higher – What’s Next?

Tvardi Therapeutics, Inc. (NASDAQ:TVRD)’s stock price was up 2.6% during trading on Wednesday . The company traded as high as $2.03 and last traded at $1.95. 167,959 shares were traded during trading, a decline of 56% from the average session volume of 385,365 shares. The stock had previously closed at $1.90.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on TVRD shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, April 10th. HC Wainwright started coverage on Tvardi Therapeutics in a report on Monday, June 8th. They issued a “buy” rating and a $9.00 price objective on the stock. Wall Street Zen cut shares of Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 4th. Finally, BTIG Research reissued a “buy” rating and issued a $15.00 price target on shares of Tvardi Therapeutics in a report on Wednesday, April 1st. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $39.80.

Tvardi Therapeutics Stock Performance

The company has a 50 day simple moving average of $3.11 and a 200 day simple moving average of $3.58. The company has a market capitalization of $18.29 million, a PE ratio of -0.63 and a beta of 0.40.

Tvardi Therapeutics (NASDAQ:TVRD) last released its earnings results on Friday, May 8th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.08). As a group, equities research analysts anticipate that Tvardi Therapeutics, Inc. will post -2.39 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. American Financial Group Inc. purchased a new position in Tvardi Therapeutics in the 4th quarter valued at $962,000. Vestal Point Capital LP purchased a new stake in Tvardi Therapeutics in the 3rd quarter valued at $6,508,000. Geode Capital Management LLC acquired a new stake in Tvardi Therapeutics during the second quarter worth about $2,617,000. Invesco Ltd. acquired a new stake in shares of Tvardi Therapeutics during the 3rd quarter worth approximately $3,219,000. Finally, Renaissance Technologies LLC increased its stake in Tvardi Therapeutics by 246.3% during the fourth quarter. Renaissance Technologies LLC now owns 104,500 shares of the company’s stock worth $449,000 after acquiring an additional 74,325 shares during the last quarter. Hedge funds and other institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.